Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the F-18-fluorodeoxyglucose-positron emission tomography era
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2015
Editora
TAYLOR & FRANCIS LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
PAULA, Henrique Moura de
CERCI, Juliano J.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
LEUKEMIA & LYMPHOMA, v.56, n.10, p.2883-2888, 2015
Resumo
Bone marrow biopsy is recommended for staging of classical Hodgkin lymphoma. The aim of this study was to compare bone marrow evaluation by histology with that obtained by F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET). One hundred and three cases of Classical Hodgkin Lymphoma were reviewed. All patients were submitted to FDG-PET evaluation. Bone marrow biopsy results were compared with clinical data and FDG-PET results. Ninety-one cases had available bone marrow biopsies. Overall, there were 16 positive and one suspect case. In five cases, the FDG-PET scan was positive and biopsy was negative: 1/5 was found to correspond to a bone fracture, 3/5 showed marked reactive bone marrow changes and in 1/5 no explanation for the discrepancy was found. FDG-PET showed high sensitivity, supporting the idea that when it is negative, biopsy could be avoided. Care should be taken in patients with a positive FDG-PET, where confirmation by bone marrow biopsy should be recommended.
Palavras-chave
Lymphoma and Hodgkin disease, morphology, prognostication
Referências
- Kremer M, 2005, VIRCHOWS ARCH, V447, P920, DOI 10.1007/s00428-005-0070-8
- Hines-Thomas MR, 2010, HAEMATOL-HEMATOL J, V95, P1691, DOI 10.3324/haematol.2010.025072
- URBA WJ, 1992, NEW ENGL J MED, V326, P678, DOI 10.1056/NEJM199203053261006
- Arber DA, 2005, AM J SURG PATHOL, V29, P1549, DOI 10.1097/01.pas.0000182405.65041.8b
- Hamilton R, 2014, LEUKEMIA LYMPHOMA, V55, P1049, DOI 10.3109/10428194.2013.821201
- Howell SJ, 2002, BRIT J HAEMATOL, V119, P408, DOI 10.1046/j.1365-2141.2002.03842.x
- Franco V, 2004, EUR J HAEMATOL, V73, P149, DOI 10.1111/j.1600-0609.2004.00292.x
- TEVELDE J, 1978, HISTOPATHOLOGY, V2, P31
- Moulin-Romsee G, 2010, EUR J NUCL MED MOL I, V37, P1095, DOI 10.1007/s00259-009-1377-5
- Salaun PY, 2009, EUR J NUCL MED MOL I, V36, P1813, DOI 10.1007/s00259-009-1183-0
- Cerci JJ, 2011, CL LYMPH MYELOM LEUK, V11, P314, DOI 10.1016/j.clml.2011.06.006
- CARBONE PP, 1971, CANCER RES, V31, P1860
- El-Galaly TC, 2014, LEUKEMIA LYMPHOMA, V55, P2349, DOI 10.3109/10428194.2013.875169
- LISTER TA, 1989, J CLIN ONCOL, V7, P1630
- MUNKER R, 1995, J CLIN ONCOL, V13, P403
- Hutchings M, 2006, HAEMATOL-HEMATOL J, V91, P482
- Mahoney DH, 1998, MED PEDIATR ONCOL, V30, P175, DOI 10.1002/(SICI)1096-911X(199803)30:3<175::AID-MPO9>3.3.CO;2-3
- Cerci JJ, 2009, CLINICS, V64, P491, DOI 10.1590/S1807-59322009000600002
- PROCTOR SJ, 1992, LEUKEMIA LYMPHOMA, V7, P17, DOI 10.3109/10428199209061558
- Cortes-Romera M, 2014, CLIN NUCL MED, V39, pE46, DOI 10.1097/RLU.0b013e31828e9504
- El-Galaly, 2012, J CLIN ONCOL, V30, P4508
- Ponzoni M, 2002, MODERN PATHOL, V15, P1273, DOI 10.1097/01.MP.0000037311.56159.13
- Roppe R., 2012, NCCN CLIN PRACTICE G
- Simpson CD, 2010, BRIT J HAEMATOL, V141, P820
- Swerdlow SH, 2008, WHO CLASSIFICATION T, P321